MedTrace Logo

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2026-03-04

No results posted yet for this study

Summary

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.

A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working.

Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.

Conditions

  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • HR Positive/HER-2 Negative Breast Cancer
  • HER2 + Breast Cancer
  • Early Stage Breast Cancer

Interventions

OTHER

There are no interventions in this observational study.

There are no interventions in this observational study.

Sponsors & Collaborators

Principal Investigators

  • Michelle Ting-Lin, MD · Tempus AI

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-27
Primary Completion
2032-12-31
Completion
2033-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211178 on ClinicalTrials.gov